In the pharmaceutical industry，R & D ability is an important evaluation indicator to measure the future development of a pharmaceutical company，R & D expenditure in the proportion of operating income (hereinafter referred to as R & D accounting) is one of the common specific parameters。With the strong support of national policy，The R & D level of domestic biomedical companies has improved。According to Fllow Shun Data Display，As of March 25，Total 67 listed companies in the pharmaceutical industry announced the 2014 R & D expenses，Total about 5.356 billion yuan。Compared with 4.271 billion yuan in 2013，R & D investment of listed pharmaceutical companies in 2014 increased by 25%。

 

    In addition，According to Fllow Shun Data Display，The average proportion of R & D expenses of these 67 listed pharmaceutical companies accounted for operating income from 4.6%in 2013 to 4.9%in 2014。

 

    stake online sports bettingstake online sports bettingShi Lichen, the person in charge of Beijing Dingchen Medical Management Consultation Center, said in an interview with the Securities Daily，The R & D investment of pharmaceutical companies in 2014 continued to increase，Especially the field of generic drugs。

 

    but，It is worth noting that it is，Increasing support for innovative enterprises in the country、Encouraging innovation to become driven by the driver of enterprise development，Compared with European and American large pharmaceutical companies，The R & D investment of domestic pharmaceutical companies is not high。

 

    R & D expenses increase

 

    Specific to listed companies，There are 16 listed companies with research and development expenses exceeding 100 million yuan，Among them, Fosun Medicine、Renfu Medicine、Lizhu Group、Bai Yunshan、Ha Yao shares、China Resources Sanjiu and other R & D expenses of R & D expenses。But the proportion of R & D expenses accounted for the operating income of listed companies，But it is another scene。

 

    Data display，Among the 67 pharmaceutical listed companies that have been announced in 2014，R & D expenses account for 26 companies with more than 5%of the operating income ratio，Among them, the proportion of Watson biological research and development costs accounted for more than 30%of operating income; followed by Anke Bio，R & D expenses accounted for nearly 16%of operating income。In addition，Guanhao Bio、Haishiko、Hanyu Pharmaceutical、R & D expenses of Shuangcheng Pharmaceuticals accounted for more than 10%of operating income。

 

    It is understood，Under the impact of patented cliff from 2013 to 2017，New drug listing speed is sharply reduced。At the same time，Countries have issued policies to stake betting appStake Sports BettingStake Sports Bettingsupport the development of generic drugs，The scale of the future generic drug market will be significantly expanded。to 2017，The proportion of generic drug markets will increase to 36%。& ldquo; Facing the huge market，Relevant domestic enterprises have also increased R & D investment。& rdquo; Shi Lichen said to reporters。

 

    but，The R & D investment of some pharmaceutical companies seems to lack sincerity。Tongliu Shun data display，R & D investment of 41 companies is less than 5%。It is a Chinese medicine shares、Tai Chi Group、The consistency of Chinese medicine、Guangyu Yuan、Tongrentang、R & D investment ratio of companies such as Southwest Pharmaceuticals is less than 1%。

 

    Analysts introduce to reporters，Different R & D investment in each company，It also has a close relationship with its industry。For example，In the field of chemical pharmaceuticals，Enterprise R & D investment accounted for the average proportion of operating income of 4.5%。In the field of Chinese medicine，The proportion of enterprise R & D investment accounted for only 2.8%。In the field of biopharmaceuticals，This average reaches 8%。In the field of medical device，This average reaches 7%。

 

    For pharmaceutical business enterprises，R & D investment overall is not high。An analyst told reporters，Current，Fields with high research and development investment in the domestic pharmaceutical industry，Most concentrated in the field of biomedical。But compared to European and American large pharmaceutical companies, the proportion of sales input in Europe and the United States，The R & D expenses of most pharmaceutical companies are not high。

 

    R & D and performance dilemma

 

    For enterprises，Increase stake online sports bettingstake sports betting appcorporate R & D investment，will reduce the profit of the enterprise to a certain extent。How to deal with the relationship between the long -term development of the enterprise and the real interests，It has always been a problem they consider。

 

    According to the introduction of Watson Bio，During the reporting period，The company further increases R & D investment，Increase the internal resource integration and sharing of the group in terms of research and development，Actively promotes the research and development progress of products in research and registered progress that has been applying for registered products。As of the end of the report，The company has a total of 21 products entering the application registration stage，Among them, 12 products are applying for clinical research，6 products are in the clinical research stage。3 products are applying for production approval。At the same time，The company has more than 10 products in preclinical research。The company's R & D expenses in 2014 were 226 million yuan。

 

    It is worth noting that it is，Listed companies increase R & D expenses，It will also affect the company's operating profit。Watson Biological R & D expenditure expenditure in 2013 was 69.1 million yuan，2014 R & D investment rose 227%。The company said in the annual report，The large increase in R & D investment has also affected the operating profit of listed companies to a certain extent。Data display，2014，Watson's biological operating income reached 719 million yuan，increased by 23%year -on -year; net profit attributable to ordinary shareholders of listed companies was 143 million yuan，increased by 199.47%year -on -year; after deducting non -recurring profit or loss，The company'Stake Sports BettingStake Sports Bettings net profit attributable to ordinary shareholders of listed companies is 443 million yuan in loss。

 

    & ldquo; This is also a problem faced by the company。High R & D cost of new drugs、Time -consuming，Some companies are more willing to choose to buy new medicines through mergers and acquisitions，instead of through its own research and development。& rdquo; An analyst of an unwilling to disclose name tells reporters。